The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities

References

• Centers for Disease Control and Prevention. Hepatitis C information for the public. Retrieved on December 12, 2010: http://www.cdc.gov/hepatitis/C/cFAQ.htm#overview
   Google Scholar
• Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis: United States, 2007. MMWR Surveill Sum 2009;58:SS-3.
   Google Scholar
• Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Bacon BR, Owens GS. Making it happen: managed care considerations in vanquishing hepatitis C. Am J Manag Care 2007;13:S327-36
   Google Scholar
• Kim WR. The burden of hepatitis C in the United States. Hepatology 2002;36(5 Suppl 1):S30-4
   PubMed Web of Science ®Google Scholar
• Leigh JP, Bowlus CL, Leistikow BN, et al. Costs of hepatitis C. Arch Intern Med 2001;161:2231-7
   PubMed Web of Science ®Google Scholar
• Wong JB, McQuillan GM, McHutchison JG, et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90:1562-9
   PubMed Web of Science ®Google Scholar
• Armstrong EP, Charland SL. Burden of illness of hepatitis C from a managed care organization perspective. Curr Med Res Opin 2004;20:671-9
   PubMed Web of Science ®Google Scholar
• Salomon JA. Weinstein MC, Hammitt JK, et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003;290:228-37
   Google Scholar
• Jacobs P, Ng YC, Stafinski T, et al. Labour force participation among individuals with hepatitis C in the US. Pharmacoeconomics 2003;21:565-72
   PubMed Web of Science ®Google Scholar
• Montoya ID, Atkinson J, Lichtiger B, et al. Prevalence of hepatitis C in a drug using and non-using welfare population. Health Policy 2003;64:221-8
   PubMedGoogle Scholar
• Su J, Brooks RA, Kleinman NL, et al. The impact of hepatitis C virus on work absence, productivity, and healthcare benefit costs. Hepatology 2010;52:436-42
   PubMed Web of Science ®Google Scholar
• Perrillo R, Rothstein KD, Rubin R, et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat 2004;11:157-65
   PubMed Web of Science ®Google Scholar
• Lim HJK, Cronkite R, Goldstein MK, et al. The impact of chronic hepatitis C and comorbid psychiatric illnesses on health-related quality of life. J Clin Gastroenterol 2006;40:528-34
   PubMed Web of Science ®Google Scholar
• Kwan JW, Cronkite RC, Yiu A, et al. The impact of chronic hepatitis C and co-morbid illnesses on health-related quality of life. Qual Life Res 2008;17:715-24
   PubMedGoogle Scholar
• Hauser W, Holtmann G, Grandt D. Determinants of health-related quality of life in patients with chronic liver disease. Clin Gastroenterol Hepatol 2004;2:157-63
   PubMed Web of Science ®Google Scholar
• Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999;29:264-70
   PubMed Web of Science ®Google Scholar
• Kallman J, O’Neil MM, Larive B, et al. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 2007;52:2531-9
   PubMed Web of Science ®Google Scholar
• Gallegos-Orozco JF, Fuentes AP, Gerado-Argueta J, et al. Health-related quality of life and depression in patients with chronic hepatitis C. Arch Med Res 2003;34:124-9
   PubMed Web of Science ®Google Scholar
• Falasca K, Mancino P, Ucciferri C, et al. Quality of life, depression, and cytokine patterns in patients with chronic hepatitis C treated with antiviral therapy. Clin Invest Med 2009;32:E212-18
   Google Scholar
• DiBonaventura MD, Wagner JS, Yuan Y, et al. Humanistic and economic impacts of hepatitis C infection in the United States. J Med Econ 2010;13:709-718
   PubMedGoogle Scholar
• Bolge SC, Doan JF, Kannan H, et al. Association of insomnia with quality of life, work productivity, and activity impairment. Qual Life Res 2009;18:415-22
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993;4:353-65
   PubMed Web of Science ®Google Scholar
• Gardner W, Mulvey EP, Shaw EC. Regression analyses of counts and rates: Poisson, overdispersed poisson, and negative binomial models. Psych Bull 1995;118:392-404
   PubMed Web of Science ®Google Scholar
• Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Proceedings of the Twenty-Six Annual SAS_Users Group International Conference, Cary, NC: SAS Institute Inc., 2004;214–26
   Google Scholar